Genome Editing as a Vehicle to Drive Successful Chimeric Antigen Receptor T Cell Therapies to the Clinic
release_4s7n4rxppvbwlgtttpwoytxw24
by
Caitlin R Hopkins,
Joseph A Fraietta
Abstract
Chimeric antigen receptor (CAR) T cells have emerged as an effective therapy for patients with relapsed and refractory haematological malignancies. However, there are many challenges preventing clinical efficacy and thus broader translation of this approach. These hurdles include poor autologous T cell fitness, manufacturing issues and lack of conserved tumour-restricted antigens to target. Recent efforts have been directed toward incorporating genome editing technologies to address these challenges and develop potent CAR T cell therapies for a diverse array of haematopoietic cancers. In this review, the authors discuss gene editing strategies that have been employed to augment CAR T cell fitness, generate allogeneic 'off-the-shelf' CAR T cell products, and safely target elusive myeloid and T cell cancers that often lack appropriate tumour-specific antigens.
In application/xml+jats
format
Archived Files and Locations
application/pdf
721.7 kB
file_b3wa4yjpibb37pfqvurgmigdci
|
emj.emg-health.com (web) web.archive.org (webarchive) |
article-journal
Stage
published
Date 2021-12-13
Open Access Publication
In DOAJ
In ISSN ROAD
Not in Keepers Registry
ISSN-L:
2397-6764
access all versions, variants, and formats of this works (eg, pre-prints)
Crossref Metadata (via API)
Worldcat
SHERPA/RoMEO (journal policies)
wikidata.org
CORE.ac.uk
Semantic Scholar
Google Scholar